secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001193125-24-011700
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus divests CIMERLI ophthalmology franchise to Sandoz for $170M upfront cash
--------------------------------------------------------------------------------

- Divestiture of CIMERLI (ranibizumab-eqrn) and supporting commercial infrastructure to Sandoz.
- Total upfront cash consideration $170M plus value of CIMERLI product inventory and working capital adjustments.
- Coherus intends to use proceeds to pay down debt, reduce interest costs, and focus on oncology (UDENYCA, LOQTORZI, pipeline).
- Closing expected first half 2024, subject to HSR antitrust waiting period expiration or termination.
- Coherus reduces headcount and overhead; J.P. Morgan and Latham & Watkins advised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312524011700/0001193125-24-011700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312524011700/d632519d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-011700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer